Brook K Baker

Oct 1, 2024 | infojustice.org | Brook K Baker

Prof. Emeritus Brook K. Baker, Northeastern U. School of LawSept. 30, 2024With little opportunity for consultation and input from civil society and other interested parties, the Government of Indonesia is considering wide-ranging amendments to its Patent Law 13 of 2016, some which will extend patent monopolies and enrich multinational drug companies at the expense of the government, patients, and other payers. Although some of proposed changes might be beneficial, others clearly are not.

Aug 15, 2024 | infojustice.org | Brook K Baker

Brook K. Baker, Professor Emeritus Northeastern U. School of Law David Deakin, MBA; BA(Hons), Independent Access AdvocateAIDS activists, researchers, and service providers are challenging Gilead’s decision to enter into narrow, bilateral voluntary licenses for its long-acting antiretroviral, lenacapavir (LEN-LA), instead of licensing much more broadly and openly with the Medicines Patent Pool (MPP).

Oct 17, 2023 | citizen.org | Peter Maybarduk |Brook K Baker |Cassidy Parshall

Introduction Today, the United States International Trade Commission (USITC) is releasing the results of its fact-finding investigation on access to COVID-19 diagnostics and therapeutics and flexibilities under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement.[1] The United States Trade Representative called for the investigation at the end of 2022, and requested information on topics ranging from supply chain and distribution to compulsory licensing and access to...

May 24, 2023 | bu.edu | Brook K Baker |Rachel Thrasher

A Way Forward for Equitable Pharmaceutical Access After COVID-19 By Brook Baker and Rachel ThrasherCOVID-19 exploded on a global stage dominated by an international legal and policy regime that instantiates closed science, intellectual property (IP) monopolies and privatized control over the testing, supply, price and distribution of life-saving health technologies.